TCGA-OR-A5LM-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.493
- INTERFERON_GAMMA_RESPONSE+0.376
- OXIDATIVE_PHOSPHORYLATION+0.373
- MTORC1_SIGNALING+0.293
- UNFOLDED_PROTEIN_RESPONSE+0.277
- GLYCOLYSIS+0.248
- MYC_TARGETS_V2+0.206
- PANCREAS_BETA_CELLS+0.180
- HYPOXIA+0.160
- CHOLESTEROL_HOMEOSTASIS+0.150
Top 10 suppressed
- TGF_BETA_SIGNALING-0.424
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.384
- APICAL_SURFACE-0.355
- WNT_BETA_CATENIN_SIGNALING-0.312
- ANGIOGENESIS-0.307
- MITOTIC_SPINDLE-0.307
- APICAL_JUNCTION-0.257
- E2F_TARGETS-0.188
- HEDGEHOG_SIGNALING-0.187
- UV_RESPONSE_DN-0.187
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_4424_T3_RNA | — | C | 0.758 |
| 2 | TCGA-OR-A5K3-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Oncocytic Type | 0.758 |
| 3 | SRR9879281 | — | cohortA4 | 0.752 |
| 4 | TCGA-UU-A93S-01A-21R-A41B-07 | — | C | 0.742 |
| 5 | AUR-ADCB-TTM1-A-1-1-R-A742-41 | — | C | 0.734 |
| 6 | AUR-AFUK-TTM1-A-1-0-R-A743-41 | — | B | 0.731 |
| 7 | MNG725 | — | — | 0.725 |
| 8 | SRR1313098 | — | C | 0.723 |
| 9 | SRR27320676 | — | — | 0.705 |
| 10 | TCGA-BH-A0EE-01A-11R-A034-07 | — | C | 0.704 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.493 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.376 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.373 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.293 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.277 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.248 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.206 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.150 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.146 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.128 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.119 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.104 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.092 | Idelalisib | — uncovered |
| PEROXISOME | 0.086 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.083 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.076 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.075 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.048 | Inavolisib | — uncovered |